Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents. 2013, Vol 2, No. 2, pp. 33-49

A review article published in Modern Chemotherapy (scientific publication) in April 2013 shows the effectiveness of Curaderm BEC5 when treating nonmalignant and very malignant skin lesions.  This study also shows the global interest in the active anticancer ingredients and their potential for the treatment of aggressive internal cancers.  To read the published article please see link: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=30489

"Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study with Curaderm BEC5"

A recent published randomised clinical trial has shown that Curaderm BEC5 eliminates over 80% of Actinic Keratoses with only 3 days of treatment.  This study also showed that 1 tube of Curaderm BEC5 can clear over 30 Actinic Keratotic lesions. See link: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=29980